The FDA expands nogapendekin alfa inbakicept in bladder cancer, European regulators back daraxonrasib in pancreatic cancer, and more.
Related to this article
The FDA set a PDUFA target action date of March 31, 2027, for tabelecleucel in relapsed or refractory EBV-positive posttransplant lymphoproliferative disease.
Read a refresh of hematologic cancer FDA and global regulatory news from September 2026.
Novel NAMPT inhibitors may circumvent the limited tolerability of previously studied agents and improve treatment outcomes in AML and MDS.
Advertisement
Advertisement
Trending on OncLive
1
Lisaftoclax Plus Acalabrutinib Received Breakthrough Therapy Designation in China for Treatment-Naive CLL/SLL
2
Tolerability Remains a TROP2-Directed ADC Hurdle in EGFR-Mutated NSCLC
3
Pembrolizumab Plus Enfortumab Vedotin Earns EC Approval in Resectable MIBC
4
Dr Sinicrope on CRC Abstracts to Watch at the 2026 ESMO Congress
5